No cardiac effects of therapeutic and supratherapeutic doses of rupatadine: results from a 'thorough QT/QTc study' performed according to ICH guidelines.
about
Rupatadine protects against pulmonary fibrosis by attenuating PAF-mediated senescence in rodentsPro-arrhythmic potential of oral antihistamines (H1): combining adverse event reports with drug utilization data across EuropePopulation pharmacokinetic modelling of rupatadine solution in 6-11 year olds and optimisation of the experimental design in younger children.Cardiovascular safety of antihistamines.Editors' pick 2010.Pharmacokinetics, Safety and Cognitive Function Profile of Rupatadine 10, 20 and 40 mg in Healthy Japanese Subjects: A Randomised Placebo-Controlled Trial.Rupatadine in Established Treatment Schemes Improves Chronic Spontaneous Urticaria Symptoms and Patients' Quality of Life: a Prospective, Non-interventional Trial.A direct comparison of efficacy between desloratadine and rupatadine in seasonal allergic rhinoconjunctivitis: a randomized, double-blind, placebo-controlled studyComparison of efficacy, safety, and cost-effectiveness of rupatadine and olopatadine in patients of allergic rhinitis: A prospective, randomized, double-blind, parallel group study.Rupatadine for the treatment of allergic rhinitis and urticaria.Rupatadine for the treatment of urticaria.Update on rupatadine in the management of allergic disorders.Cardiac Safety of Rupatadine in a Single-Ascending-Dose and Multiple-Ascending-Dose Study in Healthy Japanese Subjects, Using Intensive Electrocardiogram Assessments-Comparison With the Previous White Caucasian Thorough QT Study.Rupatadine: global safety evaluation in allergic rhinitis and urticaria.Novel targets and regulatory ordeal by QT interval.Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study.A preliminary study on efficacy of rupatadine for the treatment of acute dengue infection.
P2860
Q27311403-0C100B3B-D63E-4C41-AE72-3C25F76AF085Q28544621-BF535F70-0727-4422-B945-8623083BB97FQ33574626-65B856CB-F6E9-4A21-B7D3-4EB343E136ACQ33955706-7E28678C-9EC4-4510-BA0A-78B8532CEB6CQ34476042-0558385C-E851-45C3-A6E4-8E18E0D542F9Q36134701-2FEFFFA6-BB80-43E6-B151-95BAFA813842Q36359983-4F69DE0C-E33E-4148-95EB-DF58B185FFA7Q36638677-A4C38387-E577-460D-A47F-FF86B3188E0CQ37591598-3D1A1CC5-CC84-4FFF-8DF6-95AD4087FEE0Q37821491-59ACB3D1-0736-4E46-8630-EDF5E99317EAQ38117399-F09A2729-3FF2-4441-8430-14B2FEEC3351Q38285821-FCFE0A64-84BF-47AD-AD4B-7C7D9EE9DBA2Q38649177-3C2C7CD2-1A1F-4703-83EE-0B6061CD8ACCQ38921694-CEA3197B-58CF-41E7-B663-8D68D4EE0A29Q39871284-26D4AC0E-4AB8-49FA-BE7D-6ED7182D6403Q51406750-30049B61-1174-4775-A2F6-D6FE87111E1BQ51745540-2FF914AC-5E46-4BBD-9609-E0F12F5A7B39
P2860
No cardiac effects of therapeutic and supratherapeutic doses of rupatadine: results from a 'thorough QT/QTc study' performed according to ICH guidelines.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
No cardiac effects of therapeu ...... d according to ICH guidelines.
@ast
No cardiac effects of therapeu ...... d according to ICH guidelines.
@en
type
label
No cardiac effects of therapeu ...... d according to ICH guidelines.
@ast
No cardiac effects of therapeu ...... d according to ICH guidelines.
@en
prefLabel
No cardiac effects of therapeu ...... d according to ICH guidelines.
@ast
No cardiac effects of therapeu ...... d according to ICH guidelines.
@en
P2093
P2860
P1476
No cardiac effects of therapeu ...... ed according to ICH guidelines
@en
P2093
Anna Solans
Ester Donado
Iñaki Izquierdo
Iñaki Pérez
Joel Morganroth
Juana Peña
Manuel J Barbanoj
Olga García
Rosa M Antonijoan
P2860
P304
P356
10.1111/J.1365-2125.2009.03599.X
P407
P50
P577
2010-04-01T00:00:00Z